Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Paclitaxel and Cisplatin in Node-Positive ESCC
NCT02461043Phase 3Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Apr 2015
- Primary completion
- Dec 2020
- Modality
- Nanoparticles, Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Paclitaxel Micelles for Injection and Cisplatin micelle injection (HA132) in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Relapse-Free Survival at 3 years. Status: unknown.
02
Drugs
Paclitaxel Micelles for InjectionCisplatin micelle injection (HA132)
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02461043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02461043.